Novavax, Inc. logo


Novavax, Inc.


Earnings Summary

Net Profits
Net Profit Margins



Novavax, Inc.’s revenue jumped 60.85% since last year same period to $357.4Mn in the Q4 2022. On a quarterly growth basis, Novavax, Inc. has generated -51.35% fall in its revenue since last 3-months.

Net Profits:

Novavax, Inc.’s net profit jumped 78.46% since last year same period to $-182.25Mn in the Q4 2022. On a quarterly growth basis, Novavax, Inc. has generated -8.09% fall in its net profits since last 3-months.

Net Profit Margins:

Novavax, Inc.’s net profit margin jumped 86.61% since last year same period to -50.99% in the Q4 2022. On a quarterly growth basis, Novavax, Inc. has generated -122.16% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Novavax, Inc. post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Novavax, Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.14 - a -172.61% fall from last quarter’s estimates.

EPS Estimate Current Year:

Novavax, Inc.’s earning per share (EPS) estimates for the current year stand at -1.14.

Key Ratios

Key ratios of the Novavax, Inc. post its Q4 2022 earnings

Return on Assets (ROA)
Return on Equity (ROE)


Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Novavax, Inc.’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Novavax, Inc.’s return on equity (ROE) stands at -8.98.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Novavax, Inc. is a biotechnology company focused on delivering novel products that effectively use innovative technology to solve known and emerging disease threats. The biotechnology giant is dedicated to creating cost-effective and democratized vaccine solutions for infectious diseases, such as seasonal flu, Ebola, COVID-19, and more. Founded in 1987, Novavax, Inc. is headquartered in Gaithersburg, Maryland. It specializes in developing recombinant vaccines, and its lineup includes NVX-CoV2373, NanFlu, and ResVax, helpful in treating or preventing coronavirus, seasonal quadrivalent influenza, and a respiratory syncytial virus, respectively. Novavax, Inc. is also testing Matrix-M and its EBOV vaccine candidate in the Phase I clinical trial. It is also developing additional pre-clinical stage vaccine programs for occurrences such as MERS. It presently has over 750 employees, and its Nuvaxovid, a COVID-19 solution, is the fifth approved vaccine in the European Union. Further, Novavax has also filed the complete CMC data package with the FDA. It combines Novavax’s manufacturing prowess with Serum Institute of India Pvt. Ltd. (SII)’s experience for improved vaccine manufacturing. In addition, it also purchased Praha Vaccines and its vaccine factory in the Czech Republic, having a capacity of 1 billion doses per year. Currently Novavax, Inc. has a market cap of $0.66 Billion. It has a P.E ratio of -1.01. The shares of Novavax, Inc. are trading at $6.02. .

Novavax, Inc.
21 Firstfield Road, Gaithersburg, MD, United States, 20878
Health Technology
Stanley Erck

Trading and brokerage services provided by

Alpaca iconDrivewealth icon

Banking and Remittance services provided by

SBM icon

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*